Table of Contents Author Guidelines Submit a Manuscript

Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics and Therapeutics

Call for Papers

Hematologic malignancies consist of cancers affecting blood, bone marrow, and lymph nodes. Taken together, Chronic lymphocytic leukemia, Chronic myelogenous leukemia, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, multiple myeloma and others account for 10% of all newly diagnosed cancers each year within the United States. Recent efforts have significantly expanded our understanding of the molecular and genetic makeup of these malignancies, resulting in the development of powerful antineoplastic therapies, increased patient quality of life and extended overall survival. Unfortunately, many patients relapse and develop therapeutically unresponsive malignancies and succumb to their disease. A key to overcoming drug resistance in hematologic malignancies is an increased understanding of molecular and genetic changes to cancerous cells that leads to drug resistance. Furthermore, future findings will guide researchers in the development of novel therapeutics capable of overcoming drug resistance.

We invite authors to submit original research and review articles aiming to improve our understanding of drug resistance or offer novel therapeutic approaches to overcome drug resistance in hematologic malignancies. In particular, we are interested in articles that explore molecular changes resulting in drug resistance in hematologic malignancies and therapeutic approaches intended to target altered molecules. Potential topics include, but are not limited to:

  • Recent developments in understanding molecular changes resulting in drug resistance
  • Development and testing of novel therapeutic strategies to overcome drug resistance
  • New models to study changes in pathway signaling that results in drug resistance
  • Identifying cellular molecules involved in drug resistance that can serve as prognostic biomarkers

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Manuscript DueFriday, 15 August 2014
First Round of ReviewsFriday, 7 November 2014
Publication DateFriday, 2 January 2015

Lead Guest Editor

  • Fenghuang Zhan, Department of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, USA

Guest Editors

  • Maurizio Zangari, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
  • Lugui Qiu, Department of Lymphoma and Myeloma, Institute of Hematology, The Chinese Academy of Medical Sciences (CAMS) and The Peking Union Medical College (PUMC), Tianjin, China